# Sanyan Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sanyan-bio

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Total disclosed funding: $1.5M
- Latest round: Series A (Apr 30, 2026)
- Investors on record: 1

## About

Based in Hangzhou, China and founded in 2022, Hangzhou Sanyan Biotechnology Co., Ltd., dba Sanyan Bio, is a synthetic biotechnology company focusing on the R&D of extracellular matrix (ECM) efficacy raw materials.

In April 2026, Sanyan Bio raised over CNY 10 million in series A funding led by CCB International.

Sanyan Bio, together with its core subsidiary Hangzhou Sansheng Meijian Biotechnology Co., Ltd., leveraging its high-level expression system and AI-assisted protein design platform, develops core efficacy raw materials, including recombinant human elastin, recombinant human fibronectin, recombinant human copper-zinc superoxide dismutase (Cu/Zn-SOD), and ultra-small molecule sodium hyaluronate. The materials are applied in the medical aesthetics field for anti-aging repair, tissue regeneration, deep moisturizing, and anti-oxidation. 

The company generates revenue from developing and providing medical aesthetics and health-related raw materials.

The company will use the series A funding to expand the production capacity of functional raw materials of its core subsidiary, Hangzhou Sansheng Meijian Biotechnology Co., Ltd., upgrade AI-driven synthetic biology technology platform, and accelerate the R&D and registration application of multiple medical aesthetic pipeline products in the field of ECM.

## Funding rounds

- Series A, Apr 30, 2026, $1.5M — CCB International

## Investors

- CCB International (https://capitalatlas.ai/funds/ccb-international) — Series A